Halozyme TherapeuticsHALO +2.96%92 Days Payable is 20.15 as of Mar. 2026, which is 36% below its 10-year median of 31.60. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.32 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 705 Biotechnology companies, Halozyme Therapeutics ranks worse than 85.11% on this metric.
Halozyme Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Halozyme Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a Days Payable of 20.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Halozyme Therapeutics and its competitors. This is 36% below median its historical median of 31.60. Over the past decade, Halozyme Therapeutics' Days Payable has ranged from 7.78 to 216.55. According to the industry distribution chart, Halozyme Therapeutics ranks #600 out of 705 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Halozyme Therapeutics' Days Payable too high?
Halozyme Therapeutics' current Days Payable of 20.15 is 36% below median its 10-year median of 31.60. Over the past 10 years, this metric has ranged from a low of 7.78 to a high of 216.55. The Biotechnology industry median Days Payable is 113.36. Halozyme Therapeutics' value of 20.15 is 82.2% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #600 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Days Payable compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #600 out of 705 companies for Days Payable. This places Halozyme Therapeutics in the lower half of its industry. The industry median Days Payable is 113.36. Halozyme Therapeutics' value of 20.15 is 82.2% below this benchmark. Historically, Halozyme Therapeutics' own Days Payable has ranged from 7.78 to 216.55 over the past decade. While the company's 10-year median is 31.60 vs. the industry median of 113.36, Halozyme Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Days Payable of 20.15 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Days Payable is 20.15, which is 36% below median its own 10-year median of 31.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.32, compared to a current price of $77.18 — trading 14.5% below its estimated fair value. The current Days Payable is 20.15, which is 36% below median its 10-year median of 31.60 and 82.2% below the Biotechnology industry median of 113.36. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Days Payable is 20.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $77.18 is trading 14.5% below its estimated GF Value™ of $90.32.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Days Payable: 20.15 (36% below median its 10-year median of 31.60)
GF Value™: $90.32 vs. price of $77.18 (14.5% below fair value)
Industry Position: 82.2% below the Biotechnology median (#600 of 705)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
